Described as a type of leukemia having a rather poor prognosis, prolymphocytic leukemia (PLL) is a rare lymphoid malignancy of mature T or B cells [1] [2] [3] [4]. Prolymphocytic leukemia is primarily encountered in elderly patients, with a slight predisposition toward male gender [1] [2] [4]. In addition to the aggressive nature of this malignant disease, a very limited response to chemotherapy, and frequent relapses, a delayed diagnosis is an equally important reason for such low survival rates - 5-year survival established around 20%, while median survival is 4-7.5 months and 3 years for T-cell PLL and B-cell PLL, respectively [1] [2] [4] [5]. Although several reports have documented a rather slow clinical course of prolymphocytic leukemia, or even asymptomatic patients [1] [5], symptoms develop rapidly in the majority of cases, with splenomegaly (sometimes accompanied by hepatomegaly) and lymphadenopathy being the most prominent [1] [2] [3]. In a small, but a significant number of cases, skin lesions in the form of nodules, a maculopapular rash (either generalized or local), or erythrodermia in rare cases, are observed, and primarily appear in T-cell PLL [1] [2] [4]. Periorbital or conjunctival edema is another important feature of prolymphocytic leukemia and is more commonly seen in T-cell PLL [1]. Pleuroperitoneal serous effusions are rare complications seen in T-cell PLL, but are absent in B-cell PLL, which might be used as a distinguishing clinical feature [1] [2] [4].

A thorough diagnostic workup is mandatory in order to identify prolymphocytic leukemia in its early stages. Firstly, a detailed patient history must be obtained, during which the course, as well as the progression of symptoms, must be noted. Furthermore, palpation of the abdomen, as a component of the physical examination, will confirm the presence of splenomegaly and indicate additional testing. A complete blood count (CBC) is the cornerstone of the laboratory workup, showing profound lymphocytosis (over 100 × 109/L), whereas anemia/thrombocytopenia is observed in approximately 50% of cases [1] [2] [5]. Circulating levels of lactate dehydrogenase (LDH) are also elevated [1]. Once there is valid clinical suspicion of a lymphoproliferative process, examination of the peripheral blood smear needs to be carried out, where the presence of medium-sized prolymphocytes with intense nongranular basophilic cytoplasm containing protrusions or blebs and large (often irregular-shaped) nuclei with single prominent nucleoli is highly suggestive of a T-cell prolymphocytic leukemia [1] [4] [6]. A somewhat larger size of prolymphocytes, however, is characteristic for B-cell PLL [1]. Recognizing B-cell PLL may be challenging, because of its rather rare occurrence and similar findings compared to other mature B-cell disorders (eg. mantle cell lymphoma) [1]. To solidify the diagnosis, immunohistochemistry and phenotyping using flow cytometry is recommended - CD2, CD3, CD5 and CD7 positivity is expressed by T-cell PLL, whereas CD19, CD20, and CD22 positivity, as well as strong expression of surface membrane immunoglobulin, or SMIg, is typical for B-cell PLL [1]. For T-cell PLL, expression of T-cell receptor-1 (TCL-1) protein was examined and proposed as a prognostic factor in determining overall survival [1] [7]. Lymph node or spleen biopsies are indicated only if inconclusive findings are obtained on peripheral blood smears or when the exact type of lymphoid malignancy is not determined [1] [4]. A bone marrow biopsy will show diffuse infiltration of prolymphocytes and active hematopoiesis [4].

Treatment for Prolymphocytic Leukemia depends on the type (B-cell or T-cell) and the severity of the disease. Chemotherapy is often the first line of treatment, with drugs such as fludarabine and cyclophosphamide being commonly used. In some cases, monoclonal antibodies like alemtuzumab may be administered to target specific cancer cells. For patients with T-cell PLL, stem cell transplantation might be considered, especially in younger patients or those with aggressive disease. Supportive care, including blood transfusions and antibiotics, is also important to manage symptoms and prevent complications.

The prognosis for patients with Prolymphocytic Leukemia varies based on several factors, including the type of PLL and the patient's overall health. Generally, PLL has a poorer prognosis compared to other chronic leukemias due to its aggressive nature. B-cell PLL tends to have a slightly better prognosis than T-cell PLL. Advances in treatment, particularly targeted therapies and stem cell transplantation, have improved outcomes for some patients. However, the disease remains challenging to treat, and ongoing research is crucial to develop more effective therapies.

The exact cause of Prolymphocytic Leukemia is not well understood. Like many cancers, it is believed to result from genetic mutations that lead to uncontrolled cell growth. These mutations may occur spontaneously or be influenced by environmental factors, although specific risk factors for PLL have not been clearly identified. Research is ongoing to better understand the genetic and molecular mechanisms underlying this disease.

Prolymphocytic Leukemia is a rare condition, accounting for a small percentage of all leukemias. It predominantly affects older adults, with the average age of diagnosis being around 65 years. There is a slight male predominance in the incidence of PLL. Due to its rarity, comprehensive epidemiological data is limited, and much of the information comes from case reports and small studies.

The pathophysiology of Prolymphocytic Leukemia involves the accumulation of prolymphocytes in the blood, bone marrow, and other organs. These cells are larger and more immature than normal lymphocytes and have a high capacity for proliferation. The genetic mutations that drive PLL lead to the disruption of normal cell cycle regulation, allowing these abnormal cells to multiply unchecked. This results in the displacement of normal blood cells, leading to the symptoms and complications associated with the disease.

Currently, there are no known preventive measures for Prolymphocytic Leukemia due to the unclear etiology and risk factors. General cancer prevention strategies, such as maintaining a healthy lifestyle, avoiding exposure to known carcinogens, and regular medical check-ups, may be beneficial but are not specifically proven to prevent PLL. Ongoing research aims to identify potential risk factors and preventive strategies.

Prolymphocytic Leukemia is a rare and aggressive form of chronic leukemia characterized by the overproduction of prolymphocytes. It primarily affects older adults and presents with symptoms such as fatigue, enlarged spleen, and increased risk of infections. Diagnosis involves blood tests, bone marrow biopsy, and flow cytometry. Treatment options include chemotherapy, monoclonal antibodies, and stem cell transplantation, with the prognosis varying based on several factors. The exact cause of PLL is unknown, and there are no specific preventive measures currently available.

If you or a loved one has been diagnosed with Prolymphocytic Leukemia, it's important to understand the nature of the disease and the available treatment options. PLL is a rare type of leukemia that affects the blood and bone marrow, leading to symptoms like fatigue and enlarged organs. While it can be challenging to treat, there are therapies available that can help manage the disease and improve quality of life. It's crucial to work closely with your healthcare team to determine the best treatment plan for your specific situation. Regular follow-ups and monitoring are essential to address any changes in your condition promptly.

1. Dearden C. How I treat prolymphocytic leukemia. Blood. 2012;120(3):538-551.
2. Matutes E, Brito-Babapulle V, Swansbury J, et al. Clinical and laboratory features of 78 cases of T-prolymphocytic leukaemia. Blood. 1991;78(12):3269-3274.
3. van der Velden VH, Hoogeveen PG, de Ridder D, et al. B-cell prolymphocytic leukemia: a specific subgroup of mantle cell lymphoma. Blood. 2014;17;124(3):412-419.
4. Graham RL, Cooper B, Krause JR. T-cell prolymphocytic leukemia. Proc (Bayl Univ Med Cent). 2013;26(1):19-21.
5. Soma L, Cornfield DB, Prager D, Nowell P, Bagg A. Unusually indolent T-cell prolymphocytic leukemia associated with a complex karyotype: is this T-cell chronic lymphocytic leukemia? Am J Hematol. 2002;71(3):224-226.
6. Yoshioka Y, Nagao M, Saitoh T, et al. T-Cell Prolymphocytic Leukemia, Small Cell Variant, Possibly at the Stage of Intracytoplasmic Expression of CD3 in T-Cell Ontogenesis. J Clin Exp Hematop. 2015;55(1):17-21.
7. Herling M, Patel KA, Teitell MA, et al. High TCL1 expression and intact T-cell receptor signaling define a hyperproliferative subset of T-cell prolymphocytic leukemia. Blood. 2008;111(1):328-337.